Literature DB >> 6319464

Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature.

D A Lewis, R E Smith.   

Abstract

Although it is well-established that psychiatric symptoms can develop in association with the administration of corticosteroids, the nature of this relationship is poorly understood. We reviewed 14 previously unreported cases of steroid-induced psychiatric syndromes, 79 cases from the literature and 29 studies of the clinical efficacy of steroids in various medical illnesses. Our findings indicate that severe psychiatric reactions occur in approximately 5% of steroid-treated patients, and that a large proportion of these patients have affective and/or psychotic symptoms. Psychiatric disturbances usually occur early in the course of steroid therapy. Female sex, systemic lupus erythematosus and high doses of prednisone may be risk factors for the development of a steroid-induced psychiatric syndrome. Treatment with steroid-taper, neuroleptics or electroconvulsive therapy is generally effective, although tricyclic antidepressants do not appear to be useful therapeutic agents. Most patients recover within several weeks of the onset of symptoms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6319464     DOI: 10.1016/0165-0327(83)90022-8

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  76 in total

1.  Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review.

Authors:  S Sauerland; M Nagelschmidt; P Mallmann; E A Neugebauer
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

2.  Inhaled steroid-induced mania in an adolescent girl: a case report.

Authors:  Saira Khan; Jabeen Hayat; Shakeel Raza
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 3.  Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. A review.

Authors:  M S Bahrke; C E Yesalis; J E Wright
Journal:  Sports Med       Date:  1990-11       Impact factor: 11.136

4.  Psychiatric adverse drug reactions to glucocorticoids in children and adolescents: a much higher risk with elevated doses.

Authors:  Neda Tavassoli; Julie Montastruc-Fournier; Jean Louis Montastruc
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335

5.  Quality of life in children and adolescents 1-year after cure of Cushing syndrome: a prospective study.

Authors:  Margaret F Keil; Deborah P Merke; Roma Gandhi; Edythe A Wiggs; Kathy Obunse; Constantine A Stratakis
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-17       Impact factor: 3.478

6.  Corticosteroids and transition to delirium in patients with acute lung injury.

Authors:  Matthew P Schreiber; Elizabeth Colantuoni; Oscar J Bienvenu; Karin J Neufeld; Kuan-Fu Chen; Carl Shanholtz; Pedro A Mendez-Tellez; Dale M Needham
Journal:  Crit Care Med       Date:  2014-06       Impact factor: 7.598

7.  Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Authors:  Erminia Ridolo; P Kihlgren; I Pellicelli; M C Nizi; F Pucciarini; C Incorvaia
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 8.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

Review 9.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

Review 10.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.